Latent Tuberculosis Infection Status of Pregnant Women in Uganda Determined Using QuantiFERON TB Gold-Plus.
CD4+ T-cell and CD8+ T-cell TB responses
Uganda
latent tuberculosis infection
pregnancy
risk factors
Journal
Open forum infectious diseases
ISSN: 2328-8957
Titre abrégé: Open Forum Infect Dis
Pays: United States
ID NLM: 101637045
Informations de publication
Date de publication:
Jun 2021
Jun 2021
Historique:
received:
19
03
2021
accepted:
05
05
2021
entrez:
11
6
2021
pubmed:
12
6
2021
medline:
12
6
2021
Statut:
epublish
Résumé
The risk of progression of latent tuberculosis infection (LTBI) to active disease increases with pregnancy. This study determined the prevalence and risk factors associated with LTBI among pregnant women in Uganda. We enrolled 261 pregnant women, irrespective of gestational age. Participants who had known or suspected active tuberculosis (TB) on the basis of clinical evaluation or who had recently received treatment for TB were excluded. LTBI was defined as an interferon-γ concentration ≥0.35 IU/mL (calculated as either TB1 [eliciting CD4 LTBI prevalence was 37.9% (n = 99) (95% confidence interval [CI], 32.3-44.0). However, 24 (9.2%) subjects had indeterminate QFT-plus results. Among participants with LTBI, TB1 and TB2 alone were positive in 11 (11.1%) and 18 (18.2%) participants, respectively. In multivariable analysis, human immunodeficiency virus (HIV) infection (adjusted odds ratio [aOR], 4.4 [95% confidence interval {CI}, 1.1-18.0]; Our findings are in keeping with the evidence that HIV infection and advancing age are important risk factors for LTBI in pregnancy. In our setting, we recommend routine screening for LTBI and TB preventive therapy among eligible pregnant women.
Sections du résumé
BACKGROUND
BACKGROUND
The risk of progression of latent tuberculosis infection (LTBI) to active disease increases with pregnancy. This study determined the prevalence and risk factors associated with LTBI among pregnant women in Uganda.
METHODS
METHODS
We enrolled 261 pregnant women, irrespective of gestational age. Participants who had known or suspected active tuberculosis (TB) on the basis of clinical evaluation or who had recently received treatment for TB were excluded. LTBI was defined as an interferon-γ concentration ≥0.35 IU/mL (calculated as either TB1 [eliciting CD4
RESULTS
RESULTS
LTBI prevalence was 37.9% (n = 99) (95% confidence interval [CI], 32.3-44.0). However, 24 (9.2%) subjects had indeterminate QFT-plus results. Among participants with LTBI, TB1 and TB2 alone were positive in 11 (11.1%) and 18 (18.2%) participants, respectively. In multivariable analysis, human immunodeficiency virus (HIV) infection (adjusted odds ratio [aOR], 4.4 [95% confidence interval {CI}, 1.1-18.0];
CONCLUSIONS
CONCLUSIONS
Our findings are in keeping with the evidence that HIV infection and advancing age are important risk factors for LTBI in pregnancy. In our setting, we recommend routine screening for LTBI and TB preventive therapy among eligible pregnant women.
Identifiants
pubmed: 34113689
doi: 10.1093/ofid/ofab241
pii: ofab241
pmc: PMC8186242
doi:
Types de publication
Journal Article
Langues
eng
Pagination
ofab241Subventions
Organisme : FIC NIH HHS
ID : D43 TW011401
Pays : United States
Organisme : Medical Research Council
ID : MR/P028071/1
Pays : United Kingdom
Informations de copyright
© The Author(s) 2021. Published by Oxford University Press on behalf of Infectious Diseases Society of America.
Références
Semin Respir Crit Care Med. 2004 Jun;25(3):317-36
pubmed: 16088473
Clin Infect Dis. 2012 Dec;55(11):1532-49
pubmed: 22942202
J Neuroimmunol. 2000 Sep 1;109(1):30-3
pubmed: 10969178
J Immunol. 2004 Aug 15;173(4):2227-30
pubmed: 15294932
Ann Intern Med. 2008 Aug 5;149(3):177-84
pubmed: 18593687
Am J Respir Crit Care Med. 2012 Apr 1;185(7):779-84
pubmed: 22161161
Eur Respir J. 2011 Jan;37(1):88-99
pubmed: 21030451
Horm Behav. 2012 Aug;62(3):263-71
pubmed: 22406114
Afr Health Sci. 2015 Sep;15(3):851-60
pubmed: 26957974
BMC Infect Dis. 2010 Mar 07;10:52
pubmed: 20205938
Pulm Med. 2021 Jan 28;2021:6680651
pubmed: 33564476
PLoS One. 2016 May 05;11(5):e0154825
pubmed: 27149116
PLoS One. 2014 Nov 05;9(11):e111517
pubmed: 25372043
Obstet Gynecol. 2020 Jun;135(6):1444-1453
pubmed: 32459437
Clin Immunol. 2020 Sep;218:108523
pubmed: 32668292
Lancet Glob Health. 2014 Dec;2(12):e710-6
pubmed: 25433626
J Acquir Immune Defic Syndr. 2011 Aug 1;57(4):e77-84
pubmed: 21436710
Med Microbiol Immunol. 2019 Apr;208(2):171-183
pubmed: 30623240
BMC Infect Dis. 2015 Mar 29;15:165
pubmed: 25879423
PLoS One. 2018 Apr 4;13(4):e0193589
pubmed: 29617458
Clin Infect Dis. 2021 Mar 1;72(5):865-868
pubmed: 32374867